HR Execs on the Move

MK Education

www.mrxicorp.com

 
MK Education is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mrxicorp.com
  • 1001 Ogden Ave Ste 201
    Downers Grove, IL USA 60515
  • Phone: 630.541.3600

Executives

Name Title Contact Details

Similar Companies

Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 7,000 employees are united around our mission of improving people`s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries. Five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: People, Quality Health Care Outcomes, Customer Focus, Innovation and Efficiency.

Medsource RX

Medsource RX is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Contract Pharmaceuticals Limited

CPL is a leading contract development and manufacturing organization (CDMO) that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products.

Baxter International

Baxter International Inc. is a Fortune 500 American health care company with headquarters in Deerfield, Illinois.

Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.